Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim

Kymera Therapeutics (NASDAQ:KYMR) had its price target lifted by investment analysts at Guggenheim from $135.00 to $170.00 in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would suggest a potential upside of 43.88% from the stock’s current price.

A number of other analysts have also recently commented on the company. Wells Fargo & Company lifted their target price on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research report on Thursday. Barclays upped their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Canaccord Genuity Group increased their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. B. Riley Financial lifted their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $128.70.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $118.15 on Monday. Kymera Therapeutics has a 52 week low of $39.84 and a 52 week high of $130.05. The company’s 50 day moving average is $112.78 and its two-hundred day moving average is $93.71. The company has a market cap of $9.82 billion, a PE ratio of -36.47 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) EPS. As a group, equities research analysts expect that Kymera Therapeutics will post -3.78 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, insider Noah Goodman sold 3,389 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total transaction of $387,328.81. Following the transaction, the insider owned 47,179 shares in the company, valued at approximately $5,392,087.91. The trade was a 6.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the sale, the director directly owned 240,123 shares of the company’s stock, valued at $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,587,629 shares of company stock valued at $386,183,782 over the last 90 days. Insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Kymera Therapeutics in the second quarter valued at $344,000. California State Teachers Retirement System increased its holdings in shares of Kymera Therapeutics by 10,989.5% in the 2nd quarter. California State Teachers Retirement System now owns 6,241,373 shares of the company’s stock valued at $715,698,000 after purchasing an additional 6,185,091 shares in the last quarter. DMC Group LLC acquired a new stake in shares of Kymera Therapeutics in the second quarter valued at about $229,000. Braidwell LP lifted its stake in shares of Kymera Therapeutics by 12.0% in the second quarter. Braidwell LP now owns 378,163 shares of the company’s stock valued at $43,364,000 after purchasing an additional 40,604 shares during the period. Finally, Nykredit A S purchased a new stake in Kymera Therapeutics during the second quarter worth about $207,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.